当前位置:Public Access >页面
Chinese/English
Two-dose, Positive Drug Control, Multicenter, Randomized, Double-blind Study of rhPHT(1-34)(G56W1) Once a Week to Treat Postmenopausal Osteoporosis Women for the evaluation the PK and Safety and to Explore Therapeutic Effects.

ChiCTR注册号:

Reg No. in ChiCTR:

ChiCTR1900026859

研究题目:

Two-dose, Positive Drug Control, Multicenter, Randomized, Double-blind Study of rhPHT(1-34)(G56W1) Once a Week to Treat Postmenopausal Osteoporosis Women for the evaluation the PK and Safety and to Explore Therapeutic Effects.

Study title:

Two-dose, Positive Drug Control, Multicenter, Randomized, Double-blind Study of rhPHT(1-34)(G56W1) Once a Week to Treat Postmenopausal Osteoporosis Women for the evaluation the PK and Safety and to Explore Therapeutic Effects.

 注册状况:

 Registration:

False

注册机构:

中国临床试验注册中心

Name of the Registry:

Chinese Clinical Trial Registry

项目负责人:

中国临床试验注册中心

Corresponding person:

Chinese Clinical Trial Registry

电话:

Telephone:

18980601294

电子邮件

Email

lcyan8306@163.com

通讯地址:

成都市武侯区国学巷37号

Address:

Guoxuexiang 37#, Chengdu, Sichuan

邮政编码

Postcode

610041

项目负责人所有单位:

四川大学华西医院

Institution:

West China Hospital,Sichuan University

批准本研究的伦理委员会名称:

四川大学华西医院临床试验伦理委员会

Name of the ethic committee:

West China Hospital of Sichuan University Clinical

研究疾病:

绝经后妇女骨质疏松症

Study Ailment:

Osteoporosis in postmenopausal women

研究所处阶段:

Study phase:

Premarket

研究类型:

Type of Study:

Therapy Study

研究团队:

卢春燕、袁艳玲、黄媛媛、王倩、吴承倢、苏兰、刘明、周蔼玲

Research team:

Lu Chunyan、Yuan Yanling、Huang Yuanyuan、Wang Qian、Wu Chengjie、Su Lan、Liu Ming、Zhou Ailing

研究实施地点:

Site of Study:

国家(地区):

中国

省(直辖市):

四川

市(区县):

成都

Country/Area:

China

Province:

Sichuan

City:

Chengdu
单位 四川大学华西医院
Institution West China Hospital,Sichuan University

预计起止时间:

Planned Duration:

2019/3/8 0:00:00-2020/2/28 0:00:00